Allena Pharmaceuticals Forward PE Ratio Historical Data
The historical data trend for Allena Pharmaceuticals's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Allena Pharmaceuticals Forward PE Ratio Chart
Allena Pharmaceuticals Annual Data
Trend
2018-05
Forward PE Ratio
52.91
Allena Pharmaceuticals Quarterly Data
Forward PE Ratio
Competitive Comparison of Allena Pharmaceuticals's Forward PE Ratio
For the Biotechnology subindustry, Allena Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allena Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Allena Pharmaceuticals's Forward PE Ratio falls into.
Allena Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Allena Pharmaceuticals (OTCPK:ALNAQ) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Allena Pharmaceuticals Forward PE Ratio Related Terms
Thank you for viewing the detailed overview of Allena Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNAQ has been successfully added to your